• Vaccine Name: SARS-CoV VLP-MHV vaccine
• Target Pathogen: SARS-CoV
• Target Disease: Severe Acute Respiratory Syndrome (SARS)
• Type: Virus like particle vaccine
• Status: Research
• Host Species for Licensed Use: None
• Host Species as Laboratory Animal Model: mouse
• Antigen: SARS-CoV spike protein (S) (Tseng et al., 2012)
• Immunization Route: Intramuscular injection (i.m.)
• Description: Virus like particle vaccine produced from SARS-CoV spike protein (S) and the Nucleocapsid (N), envelope (E) and membrane (M) proteins from mouse hepatitis coronavirus (MHV) (Tseng et al., 2012)

Mouse Response

• Host Strain: BALB/c
• Host age: 6-8 weeks (Tseng et al., 2012)
• Host gender: Female (Tseng et al., 2012)
• Vaccination Protocol: Each mouse received 100 µl injection containing 2 µg of vaccine intramuscularly on days 0 and 28 (Tseng et al., 2012)
• Immune Response: Induced neutralizing antibody, Neutrophil + eosinophil infiltration, Th2-type hypersensitivity reaction. (Tseng et al., 2012)
• Side Effects: eosinophil infiltration in the lung lesions after challenge (Tseng et al., 2012)
• Challenge Protocol: On day 56 after first vaccination, each mice was challenged challenged with 106TCID50/60 µl of SARS-CoV intranasally (IN) and euthanized on day 58 (Tseng et al., 2012)
• Efficacy: protected (Tseng et al., 2012)